Breaking News on Biopharmaceutical Development & Manufacturing

Headlines > Bio Developments

TxCell raises cash for first-in-man CAR-Treg cell therapy study

24-Feb-2017 - TxCell has raised €11m ($11.6m) through a share issue which it will use to fund first-in-man study of one of its cell therapy candidates.

LegoChem signs up Novimmune as latest ADC licensee

24-Feb-2017 - LegoChem Biosciences has teamed up with Novimmune to develop and test antibody drug conjugate (ADC) drug.

Ohr Pharmaceutical Inc. shuts sustained release tech lab

23-Feb-2017 - Ohr Pharmaceutical Inc. has halted activities at the laboratory in San Diego, California where research on its sustained release delivery technology was carried out.

CRB sister Discovery launches second antibody catalogue

21-Feb-2017 - Cambridge Research Biochemicals (CRB) has launched a second catalogue of research antibodies for academia, pharma and outsourcing firms.

Sanofi hires Selexis SA for three cell line development deals

21-Feb-2017 - Sanofi has contracted Swiss biotech Selexis SA to develop cell lines for a three early stage projects.

CellGenix GmbH starts work on cell therapy regent facility expansion

21-Feb-2017 - CellGenix GmbH has started expanding its cell and gene therapy reagents facility in Freiburg, Germany citing the progression of customer projects into clinical development and commercial launch.

Belgian CRO launches EU joint venture with Chromatography Institute

20-Feb-2017 - The Research Institute for Chromatography (RIC) and Anacura have joined forces to create anaRIC biologics, an R&D and GMP analytical specialist CRO for biologics.

Selecta hires Lonza to make synthetic vector delivered gene therapy

17-Feb-2017 - Selecta Biosciences Inc. has hired Swiss contractor Lonza to make a gene therapy candidate for the metabolic disease, Methylmalonic Acidemia (MMA).

TiGenix hires Lonza to make cell therapy for Crohn's disease complications

17-Feb-2017 - TiGenix is using Lonza as a US CMO and Takeda as an ex-US commercialization partner to launch and trial its off-the-shelf stem cell therapy for a complication of Crohn’s disease....

News in brief

Charles River Labs up on biologics services

17-Feb-2017 - Charles River Laboratories says it is positioning itself to take advantage of growing demand for biological services.

Strategic CRO takes $100m hit from Pfizer's shelved PCSK9 candidate

17-Feb-2017 - Contract research organisation (CRO) ICON has taken a hit to its book-to-bill ratio after Pfizer dropped its anti-cholesterol candidate bococizumab in November.

Orgenesis granted €12.3m for GMP production ahead of clinical trials

14-Feb-2017 - Orgenesis’ Belgian subsidiary, Orgenesis SPRL, has received €12.3m ($12.8m) to further develop its Type 1 Diabetes program.

Dutch Biopharma launches Phase III trial of Leukemia donor cell therapy

14-Feb-2017 - Amsterdam-based Kiadis Biopharma has received Health Canada approval to initiate a global Phase III trial for an allogenic stem cell therapy for acute leukemia.

BriaCell files CMC amendment and preps for breast cancer vaccine trial

10-Feb-2017 - BriaCell Therapeutics Corp. has submitted a chemistry, manufacturing and control (CMC) amendment to the US FDA before its planned stem-cell based vaccine trial for late stage breast cancer. 

GE teams with Austrian research centre to optimise cell line selection

10-Feb-2017 - GE Healthcare has teamed up with the Austrian Centre of Industrial Biotechnology (acib) in an effort to remove trial and error from the cell line optimization process.

Draper looks to ultrasound and geometry to reduce CAR-T manufacturing costs

07-Feb-2017 - The Charles Stark Draper Lab has developed two microfluidic prototypes to help make the manufacturing of cell therapies cheaper and more efficient.

Rentschler: Stabilisation tech sparks 'paradigm shift' for bio-formulation services

02-Feb-2017 - Rentschler Biotechnologie has added an antibody stabilising platform to its manufacturing services through a strategic alliance with formulation tech firm Leukocare.

Lundbeck banks on shark antibody delivery tech to cross blood-brain barrier

27-Jan-2017 - Shark antibodies are an attractive way to deliver biologics to the brain, says Ossianix which is using its blood-brain barrier (BBB) crossing technology in collaboration with Lundbeck.

News in brief

Mystery San Diego party inks $300m deal with Abzena for antibody linking tech

24-Jan-2017 - An unnamed San Diego-based firm has signed a licensing agreement for Abzena Plc’s ThioBridge antibody drug conjugate (ADC) linker technology.

Horizon to use CRISPR tech to enhance CHO cell lines for biomanufacturing

17-Jan-2017 - Horizon Discovery Group has extended its CRISPR technology license to improve the performance of CHO cell lines for biomanufacturing.

News in brief

Sartorius opens Shanghai validation testing lab

13-Jan-2017 - Sartorius has bolstered its process validation services through the opening of a new validation service laboratory at a site in China.

Takeda in $125M deal for startup’s ‘unique’ Immuno-oncology platform

13-Jan-2017 - Takeda has inked a 5-year deal to finance development of T-cell therapy redirection platform from recently founded biotech, Maverick Therapeutics, with exclusive right to buy.

Amgen teams with Immatics on cancer immunotherapies

11-Jan-2017 - Amgen will manufacture, trial and sell cancer immunotherapies developed in collaboration with Immatics Biotechnologies GmbH under an agreement announced this week.

Orchard picks PharmaCell to make its autologous cell therapies

09-Jan-2017 - Orchard Therapeutics has selected Dutch CMO PharmaCell to manufacture products from its gene therapy pipeline.


Cell-in-a-Box: PharmaCyte seeks FDA advice for inoperable cancer trial

06-Jan-2017 - PharmaCyte has announced a pre-application meeting with the US FDA, to advise on their investigational new drug (IND) filing for a clinical trial its live cell encapsulation therapy.

Key Industry Events


Access all events listing

Our events, Shows & Conferences...